Gemini 4 Carbon: Our next frontier model
deepmind.google·2d ago
AI Engineering
MIT Technology Review·13h ago·5 min read
The Download: GLP-1s and eating disorders, self-aware cities, and forever chemicals
TL;DR
GLP-1 weight-loss drugs, while a significant biotech advancement, may exacerbate eating disorders, raising concerns among clinicians about their broader implications.
✦ Why It Matters
Evaluate the use of GLP-1s in patients with a history of eating disorders before prescribing.
Key Takeaways
- Monitor the mental health impacts of GLP-1s in patients.
- Explore alternative weight-loss solutions that prioritize mental well-being.
- Stay informed about regulations regarding PFAS and their environmental cleanup.
- Engage in discussions about the ethical implications of biotech advancements.
Full Summary
GLP-1s, a class of weight-loss drugs, have been hailed as a major breakthrough in biotechnology. However, a recent report indicates that their use may be contributing to a troubling increase in eating disorders, with cases of anorexia nervosa and bulimia nervosa rising by 71% globally from 1990 to 2023.
Clinicians are observing that these drugs can exacerbate existing issues related to body image and eating behaviors. In parallel, 'forever chemicals' known as PFAS, which have been used in various consumer products, pose significant health risks, including cancer and fertility issues.
Efforts to remediate PFAS-contaminated environments are still in early stages, but strategies to extract these chemicals from water systems are being explored to mitigate their harmful effects.